REDWOOD CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2025 on Wednesday, February 25, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a webcast to discuss the financial results for t ...

Group 1 - The upcoming Phase III trial for daraxonrasib, specifically the RASolute 302 study, is set to release top-line data in the first half of 2026, focusing on second-line PDAC treatment [1] - The study has dual primary endpoints of progression-free survival (PFS) and overall survival (OS), indicating that it could succeed based on either endpoint being positive, although it will be triggered by a specific number of OS events [1] - There is a question regarding the similarity of patients in the RASolute 302 study compared to the prior Phase I/II study, and the confidence in replicating the positive results from the earlier study in the larger Phase III trial [2]

Summary of Revolution Medicines Conference Call Company Overview - **Company**: Revolution Medicines (NasdaqGS: RVMD) - **Focus**: Development of targeted therapies for RAS-addicted cancers, particularly pancreatic cancer Key Points Clinical Trials and Data - **RASolute 302 Study**: - Phase 3 trial with dual primary endpoints: Progression-Free Survival (PFS) and Overall Survival (OS) [6][7] - Expected top-line data release in the first half of 2026 [6] - OS is prioritized as the main endpoint due to historical data showing PFS may not translate to survival benefits [7] - The trial is designed to be OS event-driven, with three possible outcomes: fail on both endpoints, succeed on both, or succeed on PFS but not OS [8] - **Control Arm Performance**: - Historical data indicates chemotherapy yields a PFS of 3-4 months and OS of 6-7 months in previously treated pancreatic cancer patients [11] - **Patient Population**: - The study includes both RAS mutation and wild-type patients, with a focus on G12 mutations, which represent about 85% of pancreatic cancer cases [12][14] - RAS is considered central to pancreatic cancer, with evidence suggesting that even wild-type patients may benefit from RAS-targeted therapies [12][13] Regulatory Considerations - The FDA will analyze data in various ways but will not seek statistical significance in small populations [19] - The company plans to share top-line results initially, with detailed data presented at a medical meeting [21] Future Studies - **RACELUTE 303 Study**: - A new three-arm trial for first-line metastatic pancreatic cancer patients is now open for enrollment [23] - High engagement and enthusiasm from investigators and patients are expected due to promising single-arm data from previous studies [23][25] - **Combination Therapies**: - The company is exploring multiple combination therapies, including zoldonrasib with chemotherapy, to provide more treatment options for patients [38][41] - Initial data shows that both monotherapy and combination regimens are well-tolerated and effective [35][41] Colorectal Cancer Research - The company is actively researching colorectal cancer, where 50% of patients have a RAS mutation [48] - Plans to share data on combination regimens targeting RAS and other pathways are expected later this year [49] New Developments - **RM055**: - A new class of pan-RAS inhibitors is in development, with a clinical trial expected to start by the end of the year [52] Strategic Decisions - The company opted for a global approach without partnerships, believing it to be the right decision given the complexities of managing pricing and market differentiation [55] Additional Insights - The company emphasizes the importance of providing multiple treatment options to cater to the diverse needs of patients [37] - There is a focus on the potential for post-progression use of therapies and the implications for overall survival data interpretation [30][31] This summary encapsulates the critical aspects of Revolution Medicines' conference call, highlighting their ongoing clinical trials, regulatory strategies, and future directions in cancer treatment development.

Core Insights - Revolution Medicines, Inc. is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers [3] Company Overview - The company is developing a pipeline of RAS(ON) inhibitors aimed at suppressing various oncogenic variants of RAS proteins [3] - Current clinical development includes daraxonrasib (RMC-6236), a multi-selective inhibitor; elironrasib (RMC-6291), a G12C-selective inhibitor; zoldonrasib (RMC-9805), a G12D-selective inhibitor; and RMC-5127, a G12V-selective inhibitor [3] - Additional pipeline opportunities focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C) [3] Upcoming Events - Mark A. Goldsmith, M.D., Ph.D., CEO and Chairman of Revolution Medicines, will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on February 11 at 9:30 a.m. ET [1]

Core Insights - Revolution Medicines has initiated its first-in-human clinical trial for RMC-5127, a selective inhibitor targeting the RAS G12V mutation, which is prevalent in various cancers [1][2][3] Company Overview - Revolution Medicines is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers [4] - The company's R&D pipeline includes multiple RAS(ON) inhibitors, with RMC-5127 being the fifth disclosed mutant-selective inhibitor and the fourth in clinical development [3][4] Clinical Trial Details - The trial, named RMC-5127-001, is an open-label study assessing the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of RMC-5127 as both a monotherapy and in combination settings [2] - It will enroll patients with RAS G12V–mutated solid tumors, including pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and non–small cell lung cancer (NSCLC), who have either progressed on or are intolerant to prior standard therapies [2] Market Opportunity - RAS G12V is the second most common RAS mutation, with approximately 48,000 new cases diagnosed annually in the U.S., primarily among patients with PDAC, CRC, or NSCLC [3]

Company Overview - Revolution Medicines, Inc. (NASDAQ: RVMD) is a biotechnology company focused on developing targeted therapies for cancer, known for its innovative approach to oncology, attracting interest from major pharmaceutical companies [1] Stock Performance and Analyst Ratings - Oppenheimer maintained an "Outperform" rating for RVMD, raising its price target from $75 to $150, indicating confidence in the company's future performance despite recent challenges [2][6] - RVMD's stock price recently dropped by nearly 17% after Merck withdrew from acquisition talks, with the potential deal valued between $28 billion and $32 billion [3][6] Acquisition Talks - Merck's CEO expressed interest in high-growth oncology assets, although the company typically targets acquisitions valued at $15 billion or less, which may have contributed to the stalled negotiations with RVMD [4] - AbbVie was reportedly in advanced talks to acquire Revolution Medicines earlier in January, indicating that other potential suitors may emerge, keeping the possibility of an acquisition alive [5][6] Market Capitalization and Trading Volume - Revolution Medicines' market capitalization currently stands at approximately $18.9 billion, with a trading volume of 10,173,600 shares [5]

Core Insights - Revolution Medicines (RVMD) shares fell 17% following a report that Merck (MRK) is no longer pursuing the acquisition of the company due to a disagreement over the buyout price [2][3][7] - The potential acquisition discussions may resume or attract new bidders, as both companies have not commented on the situation [3][7] - Merck was previously reported to be in talks to acquire RVMD for up to $32 billion, with a valuation range of approximately $28 billion to $32 billion being considered [4] Company Overview - Revolution Medicines is focused on developing novel drugs targeting the active, GTP-bound form of RAS proteins, referred to as RAS(ON) [5] - The lead candidate, daraxonrasib, is an investigational oral RAS(ON) multi-selective inhibitor aimed at treating various forms of cancer, including metastatic pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) [8][9] - RVMD is also developing other mutant-selective inhibitors, elironrasib and zoldonrasib, for specific RAS-bearing cancer cells [10] Pipeline Progress - Daraxonrasib is currently in late-stage studies, with data readouts expected from a phase III PDAC study in 2026 and additional phase III studies for first-line metastatic PDAC and NSCLC anticipated to begin later this year [9] - The RAS(ON) inhibitors are designed to overcome resistance mechanisms that limit the efficacy of first-generation RAS inhibitors available on the market [11] Market Performance - Over the past six months, RVMD shares have increased by 162.4%, significantly outperforming the industry average rise of 21.6% [6] - Revolution Medicines currently holds a Zacks Rank of 3 (Hold), while Alkermes (ALKS) is ranked 1 (Strong Buy) with a 26.6% increase in shares over the same period [12]

Core Viewpoint - Revolution Medicines Inc. experienced a significant decline in stock price following the cancellation of acquisition talks by Merck, which was seeking to acquire the company for $28 billion to $32 billion [2][4]. Group 1: Stock Performance - Revolution Medicines' stock fell by 16.91% to close at $97.78 after investors reacted to the news of Merck's withdrawal from acquisition negotiations [1]. - The company was highlighted as one of the worst performers in the market on that day [1]. Group 2: Acquisition Talks - Merck terminated discussions with Revolution Medicines due to disagreements over company valuation [2]. - The proposed acquisition was valued between $28 billion and $32 billion [2]. Group 3: Product Development - Revolution Medicines is advancing a pipeline of experimental medicines targeting RAS, which is crucial in treating difficult cancers [2]. - The company received a breakthrough designation from the FDA for its RAS(ON) G12D-selective inhibitor, zoldonrasib, aimed at treating specific lung cancer patients [3]. - Clinical trial results for zoldonrasib have shown a robust clinical profile, including promising antitumor activity and acceptable safety [4].

Core Viewpoint - Revolution Medicines' stock price dropped nearly 17% following reports that Merck is no longer in acquisition discussions, despite previous speculation of a deal worth tens of billions of dollars [2][3]. Group 1: Company Developments - Revolution Medicines experienced a significant decline in share price, closing at $97.92 after a drop of 16.76% [5]. - The company has a market capitalization of $23 billion, with a 52-week price range of $29.17 to $124.49 [5]. - Revolution specializes in developing oncology drugs, with its leading candidate, daraxonrasib, currently in Phase 3 clinical trials for treating pancreatic and non-small cell lung cancer [7]. Group 2: Acquisition Speculation - Reports indicated that discussions between Merck and Revolution stalled due to disagreements on the buyout price, but this does not rule out future negotiations [3]. - Other pharmaceutical companies, including AbbVie, were also reported to be interested in acquiring Revolution, although AbbVie later denied pursuing the company [4]. - Despite the setback with Merck, it is believed that Revolution could still attract a premium from other potential suitors in the future [8].

Core Viewpoint - Revolution Medicines has experienced significant stock volatility, with shares reaching an all-time high earlier this month but plummeting recently due to speculation regarding a potential acquisition by Merck and other companies [1][5]. Company Overview - Revolution Medicines operates in the oncology therapeutic space, focusing on late-stage trials for molecular inhibitors aimed at treating difficult cancers such as pancreatic, colon, and lung cancer [3][4]. - The company has not generated substantial revenue in recent years, with a slight revenue recorded in 2023 from a collaboration expiry [5]. Acquisition Speculation - There has been speculation about potential acquisition interest from Merck, with discussions valuing the company between $28 billion and $32 billion, which significantly impacts its market capitalization [5]. - Analysts suggest that the excitement around the stock is largely driven by the potential for a buyout, with over 20 analysts currently in the buy camp [6][7]. Market Performance - The stock has seen a substantial increase since August, attributed to the anticipation of FDA approval for its drugs and acquisition talks [4][10]. - The market capitalization was reported at approximately $23 billion, with the stock trading at 700 times next year's sales, which are estimated to be around $33 million [12]. Future Projections - Analysts project a potential organic milestone sales target of $10 billion for Revolution Medicines by 2035, despite the current lack of revenue [9]. - There is a significant variance in analyst ratings, with high estimates reaching $170 and lows around $73, indicating uncertainty in the stock's future performance [11][13].